Biohaven Pharmaceuticals, Inc: Lead program is rimegepant, oral CGRP antagonist (targeting migraine); recently (2Q 2019) submitted NDAs for Zydis ODT (orally dissolving tablet) and tablet formulations of rimegepant. Presented expanded data at AHS (July 2019) /dosed 1,780+ patients (combined exposure of 105k doses) and expanded safety & prelim preventive efficacy data (May 2019) from long-term safety study. Upcoming milestones: Ph 3 topline data in preventive treatment of migraine (rimegepant) & Ph 2/3 topline efficacy & safety in intranasal (BHV-3500) for acute treatment of migraine in 4Q19. Advancing ODT & tablet formulations toward commercialization. Continuing to enroll pts in Ph 2 POC in trigeminal neuralgia. Glutamate platform (focusing on troriluzole) studies ongoing in AD, OCD, GAD, and SCA.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase III
Disease Space
Central Nervous System, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM +
Therapeutic Modalities
Small Molecule
Website:
Address:
215 Church Street
New Haven, CT 06510
United States

Company Participants at Biohaven Investor Event at AAN

  • Vlad Coric, M.D., Chief Executive Officer

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.